A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf.
Natalizumab Treatment in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy
2010
Archives of Neurology
Preserved Fulltext
Objective: To study clinical and paraclinical effects of natalizumab in a patient with chronic inflammatory demyelinating polyneuropathy (CIDP). Design: Case report. Setting: Patient: A patient with highly active CIDP who did not respond to standard therapies. Intervention: Standard therapy then treatment with natalizumab (300 mg). Main Outcome Measures: Clinical disability, magnetic resonance imaging, and saturation of the ␣ 4 integrin on T lymphocytes.
doi:10.1001/archneurol.2010.143
pmid:20625098
fatcat:hknqfpill5aifkk57lvrc5eefm